Expert Consensus on the Use of Teprotumumab for the Management of Thyroid Eye Disease Using a Modified-Delphi Approach

Teprotumumab is the first treatment for thyroid eye disease (TED), a debilitating autoinflammatory condition, approved by the Food and Drug Administration in the United States, which reduces proptosis and improves quality of life. In the absence of guidelines, clinical recommendations were developed...

Descripción completa

Detalles Bibliográficos
Autores principales: Douglas, Raymond S., Kossler, Andrea L., Abrams, Jody, Briceño, Cesar A., Gay, David, Harrison, Andrew, Lee, Michael, Nguyen, John, Joseph, Shannon S., Schlachter, Dianne, Tan, Jeremy, Lynch, Judah, Oliver, Louisa, Perry, Richard, Ugradar, Shoaib
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Journal of Neuro-Ophthalmology 2022
Materias:
Original Contribution
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9377484/
https://www.ncbi.nlm.nih.gov/pubmed/35421877
http://dx.doi.org/10.1097/WNO.0000000000001560

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9377484/
https://www.ncbi.nlm.nih.gov/pubmed/35421877
http://dx.doi.org/10.1097/WNO.0000000000001560

Ejemplares similares